Stock 6160 BEIGENE, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights BeiGene, Ltd. Hong Kong S.E.

Equities

6160

KYG1146Y1017

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:27 2024-07-12 am EDT 		5-day change 1st Jan Change
93.2 HKD +4.48% Intraday chart for BeiGene, Ltd. +5.19% -15.35%
Jul. 12 Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading MT
Jul. 01 Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading
MT
Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note
MT
BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma
MT
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
CI
Beijing Gene Announces Dose the First Five Patients in Its First-In-Human Phase 1 Trial to Evaluate BG-68501
CI
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study
MT
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments
MT
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study
CI
BeiGene Says Studies Highlight Effectiveness, Safety of Lymphoma Drug Brukinsa
MT
BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
CI
Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India
MT
Glenmark Specialty S.A. Announces an Exclusive Marketing and Distribution Agreement with BeiGene
CI
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
CI
Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up
MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday
MT
BeiGene's Q1 Loss Narrows as Revenue Rises
MT
Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $752M
MT
BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
BeiGene, Ltd. Anticipates Opening of Biologics Manufacturing Facility and Clinical R&D Center at the Princeton West Innovation Campus in Hopewell, New Jersey, in July 2024
CI
Amgen Posts Higher 1Q Revenue, Swings to Loss
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BGNE Stock
  4. 6160 Stock
  5. News BeiGene, Ltd.
  6. Highlights